Validation of the Cancer BioChip System as a 3D siRNA Screening Tool for Breast Cancer Targets

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Marhefka, Joie N ^a   Abbud Antaki, Rula A ^a  

^a Falcon Genomics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CATHEPSIN V; ESTROGEN RECEPTOR ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CATALYTIC ALPHA POLYPEPTIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BIOCHIP; BREAST CANCER; CANCER BIOCHIP SYSTEM; CANCER CELL CULTURE; CANCER GROWTH; CELL STRAIN MCF 7; CELL STRAIN SK BR 3; COLONY FORMATION; CONTROLLED STUDY; GENE SILENCING; GENETIC TRANSFECTION; TUMOR GENE; VALIDATION PROCESS;

BREAST NEOPLASMS; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; FEMALE; GENOMICS; HUMANS; RECEPTOR, ERBB-2; RNA, SMALL INTERFERING;

EID: 84866883066     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046086     Document Type: Article

References (57)

1. Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, et al. (2008) Cancer proliferation gene discovery through functional genomics. Science 319: 620-624.
2. Silva JM, Marran K, Parker JS, Silva J, Golding M, et al. (2008) Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 319: 617-620.
3. Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, et al. (2010) RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Res 12: R41.
4. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, et al. (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395-402.
5. Iorns E, Lord CJ, Ashworth A, (2009) Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem J 417: 361-370.
6. Blumenthal RD, (2005) An overview of chemosensitivity testing. Methods Mol Med 110: 3-18.
7. Berwald Y, Sachs L, (1963) In Vitro Cell Transformation with Chemical Carcinogens. Nature 200: 1182-1184.
8. Abbud-Antaki RA, Marhefka JN, DeLuca AL, Zuromski MP, (2012) The Cancer BioChip System: A functional genomic assay for anchorage-independent three-dimensional breast cancer cell growth. Horm Cancer.
9. Ocana A, Pandiella A, (2008) Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options. Clin Cancer Res 14: 961-970.
10. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351: 1451-1467.
11. Mukohara T, (2011) Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer. Chemother Res Pract 2011: 730360.
12. Isaacs C, Herbolsheimer P, Liu MC, Wilkinson M, Ottaviano Y, et al. (2011) Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. Breast Cancer Res Treat 125: 137-143.
13. Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, et al. (2009) Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clin Cancer Res 15: 7693-7700.
14. Courtney KD, Corcoran RB, Engelman JA, (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28: 1075-1083.
15. Lee AV, Yee D, (2011) Targeting IGF-1R: at a crossroad. Oncology (Williston Park) 25: 535-536; discussion 551.
16. Mayer EL, Krop IE, (2010) Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res 16: 3526-3532.
17. Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, et al. (2011) HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 17: 5132-5139.
18. Munster PN, Marchion D, Thomas S, Egorin M, Minton S, et al. (2009) Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer 101: 1044-1050.
19. Abbud-Antaki RA, Marhefka JN, Deluca AL, Zuromskis MP, (2012) The Cancer BioChip System: A Functional Genomic Assay for Anchorage-Independent Three-Dimensional Breast Cancer Cell Growth. Horm Cancer.
20. Zhang JH, Chung TD, Oldenburg KR, (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
21. Brough R, Frankum JR, Sims D, Mackay A, Mendes-Pereira AM, et al. (2011) Functional viability profiles of breast cancer. Cancer Discov 1: 260-273.
22. Fu HJ, Jia LT, Bao W, Zhao J, Meng YL, et al. (2006) Stable knockdown of estrogen receptor alpha by vector-based RNA interference suppresses proliferation and enhances apoptosis in breast cancer cells. Cancer Biol Ther 5: 842-847.
23. Zang XP, Pento JT, (2008) SiRNA inhibition of ER-alpha expression reduces KGF-induced proliferation of breast cancer cells. Anticancer Res 28: 2733-2735.
24. Faltus T, Yuan J, Zimmer B, Kramer A, Loibl S, et al. (2004) Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia 6: 786-795.
25. Iorns E, Lord CJ, Grigoriadis A, McDonald S, Fenwick K, et al. (2009) Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS One 4: e5120.
26. Nencioni A, Cea M, Garuti A, Passalacqua M, Raffaghello L, et al. (2010) Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression. PLoS One 5: e9024.
27. Yamaguchi H, Condeelis J, (2007) Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta 1773: 642-652.
28. Simpson KJ, Selfors LM, Bui J, Reynolds A, Leake D, et al. (2008) Identification of genes that regulate epithelial cell migration using an siRNA screening approach. Nat Cell Biol 10: 1027-1038.
29. Wang C, Navab R, Iakovlev V, Leng Y, Zhang J, et al. (2007) Abelson interactor protein-1 positively regulates breast cancer cell proliferation, migration, and invasion. Mol Cancer Res 5: 1031-1039.
30. Kopf-Maier P, Muhlhausen SK, (1992) Changes in the cytoskeleton pattern of tumor cells by cisplatin in vitro. Chem Biol Interact 82: 295-316.
31. Ngan VK, Bellman K, Hill BT, Wilson L, Jordan MA, (2001) Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol 60: 225-232.
32. Shin IJ, Ahn YT, Kim Y, Kim JM, An WG, (2011) Actin disruption agents induce phosphorylation of histone H2AX in human breast adenocarcinoma MCF-7 cells. Oncol Rep 25: 1313-1319.
33. Kraning-Rush CM, Carey SP, Califano JP, Smith BN, Reinhart-King CA, (2011) The role of the cytoskeleton in cellular force generation in 2D and 3D environments. Phys Biol 8: 015009.
34. Chia NY, Chan YS, Feng B, Lu X, Orlov YL, et al. (2010) A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. Nature 468: 316-320.
35. Chapman HA, Riese RJ, Shi GP, (1997) Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 59: 63-88.
36. Boudreau F, Lussier CR, Mongrain S, Darsigny M, Drouin JL, et al. (2007) Loss of cathepsin L activity promotes claudin-1 overexpression and intestinal neoplasia. FASEB J 21: 3853-3865.
37. Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, et al. (2006) Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 20: 543-556.
38. Goulet B, Sansregret L, Leduy L, Bogyo M, Weber E, et al. (2007) Increased expression and activity of nuclear cathepsin L in cancer cells suggests a novel mechanism of cell transformation. Mol Cancer Res 5: 899-907.
39. Bell-McGuinn KM, Garfall AL, Bogyo M, Hanahan D, Joyce JA, (2007) Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res 67: 7378-7385.
40. Zheng X, Chu F, Chou PM, Gallati C, Dier U, et al. (2009) Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism. Am J Physiol Cell Physiol 296: C65-74.
41. Navab R, Chevet E, Authier F, Di Guglielmo GM, Bergeron JJ, et al. (2001) Inhibition of endosomal insulin-like growth factor-I processing by cysteine proteinase inhibitors blocks receptor-mediated functions. J Biol Chem 276: 13644-13649.
42. Xing R, Wu F, Mason RW, (1998) Control of breast tumor cell growth using a targeted cysteine protease inhibitor. Cancer Res 58: 904-909.
43. Fehrenbacher N, Bastholm L, Kirkegaard-Sorensen T, Rafn B, Bottzauw T, et al. (2008) Sensitization to the lysosomal cell death pathway by oncogene-induced down-regulation of lysosome-associated membrane proteins 1 and 2. Cancer Res 68: 6623-6633.
44. Dennemarker J, Lohmuller T, Mayerle J, Tacke M, Lerch MM, et al. (2010) Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis. Oncogene 29: 1611-1621.
45. Gonzalez L, Agullo-Ortuno MT, Garcia-Martinez JM, Calcabrini A, Gamallo C, et al. (2006) Role of c-Src in human MCF7 breast cancer cell tumorigenesis. J Biol Chem 281: 20851-20864.
46. Rountree MR, Bachman KE, Baylin SB, (2000) DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet 25: 269-277.
47. Chik F, Szyf M, (2011) Effects of specific DNMT gene depletion on cancer cell transformation and breast cancer cell invasion; toward selective DNMT inhibitors. Carcinogenesis 32: 224-232.
48. Tran LM, Zhang B, Zhang Z, Zhang C, Xie T, et al. (2011) Inferring causal genomic alterations in breast cancer using gene expression data. BMC Syst Biol 5: 121.
49. Warnberg F, White D, Anderson E, Knox F, Clarke RB, et al. (2006) Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo. Breast Cancer Res 8: R21.
50. Gril B, Palmieri D, Qian Y, Smart D, Ileva L, et al. (2011) Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis. Clin Cancer Res 17: 142-153.
51. Mukohara T, Shimada H, Ogasawara N, Wanikawa R, Shimomura M, et al. (2009) Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression. Cancer Lett 282: 14-24.
52. Riedemann J, Macaulay VM, (2006) IGF1R signalling and its inhibition. Endocr Relat Cancer 13Suppl 1: S33-43.
53. Fedorov Y, King A, Anderson E, Karpilow J, Ilsley D, et al. (2005) Different delivery methods-different expression profiles. Nat Methods 2: 241.
54. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR, (2003) Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 5: 834-839.
55. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R, (2003) Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 34: 263-264.
56. Birmingham A, Anderson EM, Reynolds A, Ilsley-Tyree D, Leake D, et al. (2006) 3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 3: 199-204.
57. Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, et al. (2006) Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 12: 1197-1205.